Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
39
SXTP Quote, Financials, Valuation and Earnings
Last price:
$1.87
Seasonality move
:
9.43%
Day range:
$1.75 - $1.94
52-week range:
$1.29 - $17.68
Dividend yield:
0%
P/E ratio:
15.22x
P/S ratio:
1.23x
P/B ratio:
--
Volume:
63.7K
Avg. volume:
2.3M
1-year change:
-75.2%
Market cap:
$4.6M
Revenue:
$1.4M
EPS (TTM):
-$7.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$470K | -$1.88 | 83.38% | -87% | $17.60 |
|
ABT
Abbott Laboratories
|
$11B | $1.15 | 6.19% | 54.77% | $132.28 |
|
BIVI
BioVie, Inc.
|
-- | -$0.81 | -- | -82.21% | $12.00 |
|
GDRX
GoodRx Holdings, Inc.
|
$185.4M | $0.07 | -8.68% | 145.77% | $2.82 |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -- | -- | -- | $47.50 |
|
MRNA
Moderna, Inc.
|
$239.7M | -$2.29 | 121.94% | -16.92% | $43.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
$1.86 | $17.60 | $4.6M | 15.22x | $0.00 | 0% | 1.23x |
|
ABT
Abbott Laboratories
|
$102.87 | $132.28 | $179.6B | 27.81x | $0.63 | 2.32% | 4.08x |
|
BIVI
BioVie, Inc.
|
$1.42 | $12.00 | $11M | -- | $0.00 | 0% | -- |
|
GDRX
GoodRx Holdings, Inc.
|
$2.05 | $2.82 | $721.5M | 25.01x | $0.00 | 0% | 0.94x |
|
GLSI
Greenwich LifeSciences, Inc.
|
$22.82 | $47.50 | $314.9M | -- | $0.00 | 0% | -- |
|
MRNA
Moderna, Inc.
|
$49.20 | $43.75 | $19.2B | -- | $0.00 | 0% | 9.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
3.36% | 2.681 | 1.32% | 2.18x |
|
ABT
Abbott Laboratories
|
21.33% | 0.736 | 6.98% | 1.05x |
|
BIVI
BioVie, Inc.
|
1.61% | 0.953 | 3.6% | 6.83x |
|
GDRX
GoodRx Holdings, Inc.
|
46.83% | 0.117 | 58.73% | 2.02x |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -1.545 | -- | 2.35x |
|
MRNA
Moderna, Inc.
|
13.11% | -0.316 | 11.23% | 3.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SXTP
60 Degrees Pharmaceuticals, Inc.
|
-$9.1K | -$2.3M | -186.16% | -193.16% | -439.94% | -$2.1M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
BIVI
BioVie, Inc.
|
-$57.3K | -$6.3M | -78.76% | -80.02% | -- | -$4.4M |
|
GDRX
GoodRx Holdings, Inc.
|
$154.2M | $23.8M | 2.55% | 4.7% | 12.22% | $17.1M |
|
GLSI
Greenwich LifeSciences, Inc.
|
-- | -$4.2M | -781.94% | -781.94% | -- | -$2.7M |
|
MRNA
Moderna, Inc.
|
$159M | -$857M | -26.82% | -29.19% | -126.4% | $891M |
60 Degrees Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SXTP or ABT?
Abbott Laboratories has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of 15.71%. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $17.60, signalling upside risk potential of 846.24%. On the other hand Abbott Laboratories has an analysts' consensus of $132.28 which suggests that it could grow by 28.59%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Abbott Laboratories, analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 ABTAbbott Laboratories16 7 0 -
Is SXTP or ABT More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.251%.
-
Which is a Better Dividend Stock SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.32% to investors and pays a quarterly dividend of $0.63 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SXTP or ABT?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is lower than Abbott Laboratories's net income of $1.8B. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Abbott Laboratories's PE ratio is 27.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 1.23x versus 4.08x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.1.23x 15.22x $528.6K -$2.3M ABTAbbott Laboratories4.08x 27.81x $11.5B $1.8B
-
Which has Higher Returns SXTP or BIVI?
BioVie, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of --. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat BioVie, Inc.'s return on equity of -80.02%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M BIVIBioVie, Inc.-- -$0.77 $19.6M -
What do Analysts Say About SXTP or BIVI?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $17.60, signalling upside risk potential of 846.24%. On the other hand BioVie, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 745.07%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than BioVie, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than BioVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 BIVIBioVie, Inc.1 0 0 -
Is SXTP or BIVI More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioVie, Inc. has a beta of 0.560, suggesting its less volatile than the S&P 500 by 43.997%.
-
Which is a Better Dividend Stock SXTP or BIVI?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioVie, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or BIVI?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are larger than BioVie, Inc. quarterly revenues of --. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than BioVie, Inc.'s net income of -$6.1M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while BioVie, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 1.23x versus -- for BioVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.1.23x 15.22x $528.6K -$2.3M BIVIBioVie, Inc.-- -- -- -$6.1M
-
Which has Higher Returns SXTP or GDRX?
GoodRx Holdings, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of 2.79%. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat GoodRx Holdings, Inc.'s return on equity of 4.7%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M GDRXGoodRx Holdings, Inc.79.16% $0.02 $1.2B -
What do Analysts Say About SXTP or GDRX?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $17.60, signalling upside risk potential of 846.24%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $2.82 which suggests that it could grow by 37.34%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than GoodRx Holdings, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than GoodRx Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 GDRXGoodRx Holdings, Inc.4 8 0 -
Is SXTP or GDRX More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.781%.
-
Which is a Better Dividend Stock SXTP or GDRX?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or GDRX?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $194.8M. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is lower than GoodRx Holdings, Inc.'s net income of $5.4M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while GoodRx Holdings, Inc.'s PE ratio is 25.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 1.23x versus 0.94x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.1.23x 15.22x $528.6K -$2.3M GDRXGoodRx Holdings, Inc.0.94x 25.01x $194.8M $5.4M
-
Which has Higher Returns SXTP or GLSI?
Greenwich LifeSciences, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of --. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Greenwich LifeSciences, Inc.'s return on equity of -781.94%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M GLSIGreenwich LifeSciences, Inc.-- -$0.30 $2.2M -
What do Analysts Say About SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $17.60, signalling upside risk potential of 846.24%. On the other hand Greenwich LifeSciences, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 108.15%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Greenwich LifeSciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 GLSIGreenwich LifeSciences, Inc.2 0 0 -
Is SXTP or GLSI More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Greenwich LifeSciences, Inc. has a beta of 1.538, suggesting its more volatile than the S&P 500 by 53.805%.
-
Which is a Better Dividend Stock SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Greenwich LifeSciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Greenwich LifeSciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or GLSI?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are larger than Greenwich LifeSciences, Inc. quarterly revenues of --. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Greenwich LifeSciences, Inc.'s net income of -$4.2M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Greenwich LifeSciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 1.23x versus -- for Greenwich LifeSciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.1.23x 15.22x $528.6K -$2.3M GLSIGreenwich LifeSciences, Inc.-- -- -- -$4.2M
-
Which has Higher Returns SXTP or MRNA?
Moderna, Inc. has a net margin of -438.1% compared to 60 Degrees Pharmaceuticals, Inc.'s net margin of -121.83%. 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16% beat Moderna, Inc.'s return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital SXTP60 Degrees Pharmaceuticals, Inc.-1.72% -$0.66 $4.5M MRNAModerna, Inc.23.45% -$2.11 $10B -
What do Analysts Say About SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. has a consensus price target of $17.60, signalling upside risk potential of 846.24%. On the other hand Moderna, Inc. has an analysts' consensus of $43.75 which suggests that it could fall by -11.08%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTP60 Degrees Pharmaceuticals, Inc.2 0 0 MRNAModerna, Inc.2 17 1 -
Is SXTP or MRNA More Risky?
60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.144%.
-
Which is a Better Dividend Stock SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 60 Degrees Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTP or MRNA?
60 Degrees Pharmaceuticals, Inc. quarterly revenues are $528.6K, which are smaller than Moderna, Inc. quarterly revenues of $678M. 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M is higher than Moderna, Inc.'s net income of -$826M. Notably, 60 Degrees Pharmaceuticals, Inc.'s price-to-earnings ratio is 15.22x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 60 Degrees Pharmaceuticals, Inc. is 1.23x versus 9.69x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTP60 Degrees Pharmaceuticals, Inc.1.23x 15.22x $528.6K -$2.3M MRNAModerna, Inc.9.69x -- $678M -$826M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
